Nike Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nike Inc trades at $42.97 (market cap $64.49B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Nike Inc is far larger — about 42.2× Recursion Pharmaceuticals Inc's market cap, and Nike Inc pays a 3.77% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NKE | RXRX | |
|---|---|---|
Market Cap | $64.49B | $1.53B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $79.24 | $6.79 |
52-Week Low | $40.75 | $2.84 |
Enterprise Value | $66.49B | $946.50M |
Dividend Yield | 3.77% | — |
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $43.76, down 1.82% on the day, with a neutral technical signal and bullish moving averages. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.72 surpassing the $0.11 estimate. Revenue declined to $46.31B in 2025, while net income margin compressed to 6.7%. The stock holds a consensus analyst price target of $50.80, with 49% of analysts rating it a Buy. A dividend of $0.41 is scheduled for payment on July 1, 2026.
Nike's outlook is mixed: strong brand equity and earnings beats support upside potential, but revenue pressures and margin compression pose risks. Investors face trade-offs between valuation support and execution challenges in key markets like China. The stock's current discount to consensus target suggests cautious optimism amid turnaround efforts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →